-
公开(公告)号：US10183009B2
公开(公告)日：2019-01-22
申请号：US15592013
申请日：2017-05-10
发明人： Brian K. Albrecht , Steven F. Bellon , Daniel J. Burdick , Alexandre Cote , Terry Crawford , Les A. Dakin , Vickie Hsiao-Wei Tsui , Michael Charles Hewitt , Yves LeBlanc , Steven R. Magnuson , Christopher G. Nasveschuk , F. Anthony Romero , Yong Tang , Alexander M. Taylor , Shumei Wang
IPC分类号： A61K31/40 , C07D471/04
摘要： The present invention relates to compounds of formula (I): and to salts thereof, wherein R1, R2, and Q have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of bromodomains. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated disorders.
-
公开(公告)号：US10155764B2
公开(公告)日：2018-12-18
申请号：US15449692
申请日：2017-03-03
发明人： Brian K. Albrecht , Alexandre Cote , Terry Crawford , Martin Duplessis , Andrew Charles Good , Yves LeBlanc , Steven Magnuson , Christopher G. Nasveschuk , Richard Pastor , Anthony F. Romero , Alexander M. Taylor
IPC分类号： C07D487/04 , C07D403/12 , C07D401/12 , C07D237/32 , C07D471/04 , A61K31/502 , A61K31/5025 , A61K31/5377 , A61K31/55 , C07D237/34 , C07D405/12
摘要： The present invention relates to methods for treating PCAF and GCN5 mediated disorders using a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein ring A, R1, R3, R4, R5, and each Re have any of the values defined in the specification. Also included are novel compounds of Formula (I) and salts thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20170342067A1
公开(公告)日：2017-11-30
申请号：US15592017
申请日：2017-05-10
发明人： Brian K. Albrecht , Steven F. Bellon , Daniel J. Burdick , Alexandre Cote , Terry Crawford , Les A. Dakin , Vickie Hsiao-Wei Tsui , Michael Charles Hewitt , Yves LeBlanc , Steven R. Magnuson , Christopher G. Nasveschuk , Anthony F. Romero , Yong Tang , Alexander M. Taylor , Shumei Wang
IPC分类号： C07D471/04 , A61K45/06 , A61K31/4985 , A61K31/496 , A61K31/4545 , C07D519/00 , A61K31/437
CPC分类号： C07D471/04 , A61K31/437 , A61K31/4545 , A61K31/496 , A61K31/4985 , A61K45/06 , C07D519/00
摘要： The present invention relates to compounds of formula (I): and to salts thereof, wherein R1, R2, and Q have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of bromodomains. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated disorders.
-
公开(公告)号：US20170340605A1
公开(公告)日：2017-11-30
申请号：US15592013
申请日：2017-05-10
发明人： Brian K. Albrecht , Steven F. Bellon , Daniel J. Burdick , Alexandre Cote , Terry Crawford , Les A. Dakin , Vickie Hsiao-Wei Tsui , Michael Charles Hewitt , Yves LeBlanc , Steven R. Magnuson , Christopher G. Nasveschuk , Anthony F. Romero , Yong Tang , Alexander M. Taylor , Shumei Wang
IPC分类号： A61K31/40 , C07D471/04
CPC分类号： A61K31/40 , C07D471/04
摘要： The present invention relates to compounds of formula (I): and to salts thereof, wherein R1, R2, and Q have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of bromodomains. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated disorders.
-
公开(公告)号：US20170334883A1
公开(公告)日：2017-11-23
申请号：US15449706
申请日：2017-03-03
发明人： Brian K. Albrecht , Alexandre Cote , Terry Crawford , Martin Duplessis , Andrew Charles Good , Yves LeBlanc , Steven Magnuson , Christopher G. Nasveschuk , Richard Pastor , Anthony F. Romero , Alexander M. Taylor
IPC分类号： C07D403/12 , C07D401/12 , C07D401/04 , C07D253/075 , A61K45/06 , C07D403/04 , A61K31/53
CPC分类号： C07D403/12 , A61K31/53 , A61K45/06 , A61P35/00 , C07D249/12 , C07D253/075 , C07D401/04 , C07D401/12 , C07D403/04
摘要： The present invention relates to methods for treating PCAF mediated disorders using a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R1, R3-R6, X, and each Re have any of the values defined in the specification. Also included are novel compounds of formula (I) and salts thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US10316023B2
公开(公告)日：2019-06-11
申请号：US15449706
申请日：2017-03-03
发明人： Brian K. Albrecht , Alexandre Cote , Terry Crawford , Martin Duplessis , Andrew Charles Good , Yves LeBlanc , Steven Magnuson , Christopher G. Nasveschuk , Richard Pastor , F. Anthony Romero , Alexander M. Taylor
IPC分类号： C07D249/12 , C07D403/04 , C07D403/12 , C07D401/04 , C07D401/12 , A61K31/53 , A61K31/4196 , A61P35/00 , C07D253/075 , A61K45/06
摘要： The present invention relates to methods for treating PCAF mediated disorders using a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R1, R3-R6, X, and each Re have any of the values defined in the specification. Also included are novel compounds of formula (I) and salts thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US10239861B2
公开(公告)日：2019-03-26
申请号：US15643801
申请日：2017-07-07
发明人： Brian K. Albrecht , Daniel J. Burdick , Alexandre Cote , Martin Duplessis , Christopher G. Nasveschuk , Alexander M. Taylor
IPC分类号： C07D401/12 , C07D403/12 , C07D401/14 , C07D405/14 , C07D413/14 , C07D405/12 , A61K31/501 , A61K31/55 , A61K45/06 , C07D451/04
摘要： The invention relates to compounds of formula (I) and salts thereof: wherein R1-R3 have any of the values defined in the specification. The compounds and salts are useful for treating PCAF mediated disorders and/or GCN5 mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as and methods of using said compounds, salts, or compositions in the treatment of various disorders.
-
公开(公告)号：US20180086720A1
公开(公告)日：2018-03-29
申请号：US15686028
申请日：2017-08-24
发明人： Brian K. Albrecht , Alexandre Cote , Terry Crawford , Martin Duplessis , Andrew Charles Good , Yves LeBlanc , Steven R. Magnuson , Christopher G. Nasveschuk , Anthony F. Romero , Yong Tang , Alexander M. Taylor
IPC分类号： C07D237/20 , C07D401/12 , C07D401/04 , C07D487/04 , C07D403/04 , C07D487/08 , C07D498/10 , C07D471/10 , C07D403/14 , C07D413/12 , C07D403/12 , C07D413/14 , C07D405/14 , C07D417/14 , C07D237/22 , C07D451/02 , C07D413/04
CPC分类号： C07D237/20 , A61K31/337 , A61K31/437 , A61K31/501 , A61K45/06 , C07D237/22 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/14 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/14 , C07D451/02 , C07D471/10 , C07D487/04 , C07D487/08 , C07D498/10 , A61K2300/00
摘要： The present invention relates to compounds of formula (I): and salts thereof, wherein: R1-R4 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of BRG1, BRM and/or PB1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various BRG1-mediated disorders, BRM-mediated disorders and/or PB1-mediated disorders.
-
公开(公告)号：US20180037566A1
公开(公告)日：2018-02-08
申请号：US15643801
申请日：2017-07-07
发明人： Brian K. Albrecht , Daniel J. Burdick , Alexandre Cote , Martin Duplessis , Christopher G. Nasveschuk , Alexander M. Taylor
IPC分类号： C07D401/12 , A61K31/55 , A61K45/06 , C07D405/14 , C07D451/04 , C07D401/14 , C07D405/12 , C07D403/12 , A61K31/501
CPC分类号： C07D401/12 , A61K31/501 , A61K31/55 , A61K45/06 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D413/14 , C07D451/04
摘要： The invention relates to compounds of formula (I) and salts thereof: wherein R1-R3 have any of the values defined in the specification. The compounds and salts are useful for treating PCAF mediated disorders and/or GCN5 mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as and methods of using said compounds, salts, or compositions in the treatment of various disorders.
-
公开(公告)号：US20170312292A1
公开(公告)日：2017-11-02
申请号：US15482581
申请日：2017-04-07
发明人： Anthony F. Romero , Steven R. Magnuson , Richard Pastor , Vickie Hsiao-Wei Tsui , Jeremy Murray , Terry Crawford , Daniel J. Burdick , Brian K. Albrecht , Alexandre Cote , Alexander M. Taylor , Christopher G. Nasveschuck , Yves LeBlanc , Michael Charles Hewitt , Kwong Wah Lai , Kevin Chen
IPC分类号： A61K31/55 , C07D403/04 , C07D243/24 , A61K31/5513 , C07D243/12 , C07D223/16 , C07D403/14 , C07D267/14
CPC分类号： A61K31/55 , A61K31/337 , A61K31/5513 , A61K45/06 , C07D223/16 , C07D243/12 , C07D243/24 , C07D267/14 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/14 , C07D405/04 , C07D405/12 , C07D413/04 , C07D413/10 , C07D471/04 , C07D495/04 , A61K2300/00
摘要： The present invention relates to compounds of formula (I): and to salts thereof, wherein A has any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
-
-
-
-
-
-
-
-
-
搜索结果
69 条记录 (耗时 0.04 秒)
